Routine eye test leads to devastating diagnosis for Royal Navy man
A FORMER submariner from Bishopton has spoken out after his devastating diagnosis which forced him to give up his job.
Source: glasgowtimes.co.uk
Retinal Dystrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Retinal Dystrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Retinal Dystrophy Today - Breaking & Trending Today
Rainbow Genomics Launches Retinal Dystrophy (Eye Disorders) Test Using Dual Whole-Exome and 300-Gene Deep Sequencing
Dual Sequencing Approach Determines Both Novel Variants Specific to Asian Patients, and Challenging Mutations Not Easily Detected by Routine Sequencing Methods
Source: einnews.com
Mason's guide dogs fundraiser surpasses £5k thanks to Llanidloes Rotary support
A severely sight impaired boy who has raised thousands of pounds by walking across mid Powys has received a cheque for £100 from Llanidloes Rotary…
Source: countytimes.co.uk
Investegate |MeiraGTx Announcements | MeiraGTx: MeiraGTx Reports First Quarter 2021 Financial and Operational Results
MeiraGTx Reports First Quarter 2021 Financial and Operational Results LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. “During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are exc...
Source: investegate.co.uk
MeiraGTx Reports First Quarter 2021 Financial and Operational Results
MeiraGTx Reports First Quarter 2021 Financial and Operational Results LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. "During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited ...
Source: finanznachrichten.de